Work

CLL-429: Daybreak CLL-201: A Study of Bexobrutideg (NX-5948), a Bruton Tyrosine Kinase Degrader, in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Previously Treated With a Covalent BTK Inhibitor, a Noncovalent BTK Inhibitor, and a BCL2 Inhibitor

Year: 2026

Type: conference-abstract

Source: Clinical Lymphoma Myeloma & Leukemia

DOI: 10.1016/s2152-2650(26)02042-2

Authors: Michael Tees, Paolo Ghia, Dima El-Sharkawi, Michal Kwiatek, Sebastien Grosicki, Anne Lok, Jane Robertson, Krish Patel, Iwona Hus, Lucy Yan, Srinand Nandakumar, Kelly O'Brien, Wojciech Jurczak

Institutions: Colorado Blood Cancer Institute, Vita-Salute San Raffaele University, Royal Marsden NHS Foundation Trust, Medical University of Silesia, Centre Hospitalier Universitaire de Nantes, Nantes Université, The Christie Hospital, Cancer Research UK Manchester Centre, Sarah Cannon, Medical University of Lublin, The Maria Sklodowska-Curie National Research Institute of Oncology

Language: English

Topic: Chronic Lymphocytic Leukemia Research

Subfield: Genetics

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W7204708010

Cites:

Cited by:

Related to: